In the process of investigating the nature of the immune response to alloantigens in rat models of organ transplantation, the applicants have employed synthetic peptides, which represent the polymorphic, antigenic motifs which can immunize or tolerize to MHC molecules. T lymphocyte recognition of such peptides is via the physiological pathway of antigen presentation by antigen presenting cells of the host, termed the indirect pathway of allo-recognition, because other clones of T cells recognize intact allo-MHC molecules directly on donor cells. The oral route of administration of donor antigen in the form of lymphocytes or synthetic peptides can suppress the development of the TH1 immune response in an antigen-specific manner, while intra-thymic injection produces a completely tolerant state, preventing acute and chronic rejection by tolerizing via the indirect pathway to donor class II MHC. The applicants hypothesized a failure to suppress T cell responses via the indirect pathway lies at the heart of the chronic rejection process. They plan to study human transplant recipients, based on preliminary results which show that patients having chronic renal allograft rejection have primed T cells to donor HLA-DR peptides. First, they will follow prospectively a series of transplant recipients over a three year period to determine their pattern of response to MHC allopeptides in relation to clinical events. The hypothesis is that responders will develop chronic rejection, while hyporesponsive patients are protected from developing the process. Second, they will generate allopeptide-specific T cell clones from examples of responsive and hyporesponsive patients, to define the HLA-restriction patterns as well as T cell receptor gene expression and cytokine patterns. Third, they will institute experiments of feeding the relevant donor HLA-DR peptides to patients with chronic rejection in an attempt to specifically down-regulate the immune response via the indirect pathway, as this will be an initial feasibility study towards development of new therapeutic strategies to prevent development or interrupt progression of chronic rejection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI033100-08
Application #
6137174
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Prasad, Shiv A
Project Start
1992-07-01
Project End
2002-12-31
Budget Start
2000-01-01
Budget End
2000-12-31
Support Year
8
Fiscal Year
2000
Total Cost
$346,585
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Womer, Karl L; Magee, Colm C; Najafian, Nader et al. (2008) A pilot study on the immunological effects of oral administration of donor major histocompatibility complex class II peptides in renal transplant recipients. Clin Transplant 22:754-9
Salama, Alan D; Najafian, Nader; Clarkson, Michael R et al. (2003) Regulatory CD25+ T cells in human kidney transplant recipients. J Am Soc Nephrol 14:1643-51
Kist-van Holthe, Joana E; Gasser, Martin; Womer, Karl et al. (2002) Regulatory functions of alloreactive Th2 clones in human renal transplant recipients. Kidney Int 62:627-31
Donato, Jose L; Ko, Jon; Kutok, Jeffery L et al. (2002) Human HTm4 is a hematopoietic cell cycle regulator. J Clin Invest 109:51-8
Najafian, Nader; Salama, Alan D; Fedoseyeva, Eugenia V et al. (2002) Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: potential novel assay for prediction of outcomes for renal transplant recipients. J Am Soc Nephrol 13:252-9
Frank, M H; Denton, M D; Alexander, S I et al. (2001) Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. J Immunol 166:2451-9
Stadlbauer, T H; Schaub, M; Magee, C C et al. (2000) Intrathymic immunomodulation in sensitized rat recipients of cardiac allografts: requirements for allorecognition pathways. J Heart Lung Transplant 19:566-75
Murphy, B; Magee, C C; Alexander, S I et al. (1999) Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis. J Clin Invest 103:859-67
Onodera, K; Chandraker, A; Volk, H D et al. (1999) Distinct tolerance pathways in sensitized allograft recipients after selective blockade of activation signal 1 or signal 2. Transplantation 68:288-93
Lara-Marquez, M L; Deykin, A; Krinzman, S et al. (1998) Analysis of T-cell activation after bronchial allergen challenge in patients with atopic asthma. J Allergy Clin Immunol 101:699-708

Showing the most recent 10 out of 40 publications